• Home
  • Investors
  • PRINT

No More Pricks – Quick Dissolvable Tablet is Set to Disrupt the Vaccine Industry

White Coat Productions documentary in development explores the global impact of vaccine delivery advancements

Category:

Thursday, August 10, 2017 8:00 am EDT

Dateline:

WASHINGTON

Public Company Information:

NYSE:
CTLT

WASHINGTON--(BUSINESS WIRE)--The quest to improve vaccination efforts in developing nations may yield huge side benefits to the industrialized world; an end to needle injections.

Catalent scientists have developed a quick dissolving tablet they hope can provide an option to replace some needle injections for vaccination. Imagine back-to-school doctor visits without your children kicking and screaming, afraid of their doctor’s syringe!

There are clear additional benefits in the efforts to vaccinate impoverished populations in remote corners of the world. Currently, many vaccines require a “cold-chain” so their temperature is maintained constantly by refrigeration throughout delivery. The need for a cold chain is a serious obstacle in trying to reach regions where refrigeration isn’t available, and where temperatures are often higher.

Recently published in the journal Vaccine, Johns Hopkins Bloomberg School of Health Professor Bruce Lee, M.D. reports of a significant economic advantage in developing temperature stable vaccines.

As part of an effort to eliminate the cold chain, scientists using temperature stable Zydis® technology are customizing their formulations and say they are on the cutting edge of manufacturing vaccine doses that dissolve on the tongue within a few seconds, eliminating the need for needle injections, which can also pose challenges for maintaining sterility in some environments.

Research and development is currently being conducted at Catalent’s laboratories in Swindon, U.K., where chemists have already been successful in developing commercial platforms for treatments such as immunotherapy for allergy relief.

A documentary on the need for improved vaccination deployment is in development at White Coat Productions, a video content creation firm based in the DC/Baltimore metro area.

Video news release available at the following link: https://vimeo.com/227783144
SME’s available on appointment basis

Zydis is a registered trademark of R.P. Scherer Technologies, Inc., a subsidiary of Catalent Pharma Solutions, Inc. Used with permission.

Multimedia Files:

Watch this video
No Pricks - Vaccine Development (Video: Business Wire)
Preview image

Contact:

White Coat Productions
David Wasser, 202-256-4709
or
Pat Brogan, 703-462-0530
WhiteCoatProductions@gmail.com

Investor Contact

Investor Relations Dept
Catalent, Inc.
14 Schoolhouse Road
Somerset, NJ 08873

Phone +1 732 537 6325
Fax +1 732 537 5932
investors@catalent.com

development
With our broad range of expert services, we drive faster, more efficient development timelines and produce better products.
delivery
We are a world leader in drug delivery solutions with a proven track record of helping our customers create better treatments.
supply
As a seamless extension of your supply chain, we offer global integrated manufacturing and packaging solutions.